Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Enterprise Value (2019 - 2025)

Vivos Therapeutics' Enterprise Value history spans 7 years, with the latest figure at -$2.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$2.1 million for Q4 2025, up 66.63% from a year ago — trailing twelve months through Dec 2025 was -$2.1 million (up 66.63% YoY), and the annual figure for FY2025 was -$2.1 million, up 66.63%.
  • Enterprise Value for Q4 2025 was -$2.1 million at Vivos Therapeutics, up from -$3.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.0 million in Q3 2023 to a low of -$34.2 million in Q2 2021.
  • The 5-year median for Enterprise Value is -$6.3 million (2024), against an average of -$9.5 million.
  • The sharpest move saw Enterprise Value surged 85.34% in 2022, then crashed 531.1% in 2024.
  • Year by year, Enterprise Value stood at -$24.0 million in 2021, then surged by 85.34% to -$3.5 million in 2022, then soared by 53.31% to -$1.6 million in 2023, then crashed by 281.01% to -$6.3 million in 2024, then soared by 66.63% to -$2.1 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$2.1 million, -$3.1 million, and -$4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.